American pharmaceutical company Johnson & Johnson's announcement that it temporarily paused its Covid-19 vaccine clinical trial is yet another blow for those banking on a speedy end to the coronavirus pandemic.
Such a misstep is what fund managers including Barry Norris, chief executive of Argonaut Capital is betting on. J&J's stock sank more than 1% in New York premarket trading.
